Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China

Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China

Introduction Persistent diabetic macular edema (DME) with inadequate responsiveness to conventional inhibitors of vascular endothelial growth factor (VEGF) has caused significant vision loss and substantial treatment burdens. Brolucizumab is a new-generation anti-VEGF agent with better anatomical ef...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Li, Dan Cao, Honghua Yu, Yunyan Hu, Yijun Hu, Ying Fang, Jiahui Zeng, Anyi Liang, Ziyi Huang, Chenxiao Shen, Huiyi Liao, Chunwen Zheng, Shuyi Ouyang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/7/e099551.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://bmjopen.bmj.com/content/15/7/e099551.full

Similar Items